| Strategies to overcome DC dysregulation in the tumor microenvironment G Mestrallet, K Sone, N Bhardwaj Frontiers in immunology 13, 980709, 2022 | 42 | 2022 |
| Immune escape and resistance to immunotherapy in mismatch repair deficient tumors G Mestrallet, M Brown, CC Bozkus, N Bhardwaj Frontiers in Immunology 14, 1210164, 2023 | 37 | 2023 |
| Anti‐HIV‐1 antibodies trigger non‐lytic complement deposition on infected cells J Dufloo, F Guivel‐Benhassine, J Buchrieser, V Lorin, L Grzelak, ... EMBO reports 21 (2), e49351, 2020 | 34 | 2020 |
| Skin immunity and tolerance: focus on epidermal keratinocytes expressing HLA-G G Mestrallet, N Rouas-Freiss, J LeMaoult, NO Fortunel, MT Martin Frontiers in immunology 12, 772516, 2021 | 29 | 2021 |
| Methods for establishing a renal cell carcinoma tumor spheroid model with immune infiltration for immunotherapeutic studies L Lugand, G Mestrallet, R Laboureur, C Dumont, F Bouhidel, M Djouadou, ... Frontiers in Oncology 12, 898732, 2022 | 18 | 2022 |
| Human Keratinocytes Inhibit CD4+ T-Cell Proliferation through TGFB1 Secretion and Surface Expression of HLA-G1 and PD-L1 Immune Checkpoints G Mestrallet, F Auvré, C Schenowitz, ED Carosella, J LeMaoult, MT Martin, ... Cells 10 (6), 1438, 2021 | 12 | 2021 |
| Software development for severe burn diagnosis and autologous skin substitute production G Mestrallet Computer Methods and Programs in Biomedicine Update 2, 100069, 2022 | 8 | 2022 |
| Predicting Immunotherapy Outcomes in Glioblastoma Patients through Machine Learning G Mestrallet Cancers 16 (2), 408, 2024 | 5 | 2024 |
| Software development to estimate herd profitability according to nutrition parameters. G Mestrallet agriRxiv, 20230009899, 2023 | 5 | 2023 |
| Immunosuppressive properties of epidermal keratinocytes differ according to their immaturity status G Mestrallet, ED Carosella, MT Martin, N Rouas-Freiss, NO Fortunel, ... Frontiers in Immunology 13, 2022 | 5 | 2022 |
| Predicting Resistance to Immunotherapy in Melanoma, Glioblastoma, Renal, Stomach and Bladder Cancers by Machine Learning on Immune Profiles G Mestrallet Onco 4 (3), 192-206, 2024 | 3 | 2024 |
| Prediction of Glioma Resistance to Immune Checkpoint Inhibitors Based on Mutation Profile G Mestrallet Neuroglia 5 (2), 145-154, 2024 | 3 | 2024 |
| Leveraging Tumor Mutation Profiles to Forecast Immune Checkpoint Blockade Resistance in Melanoma, Lung, Head and Neck, Bladder and Renal Cancers G Mestrallet Onco 4 (4), 439-457, 2024 | 1 | 2024 |
| Fraction of Genome Altered, Age, Microsatellite Instability Score, Tumor Mutational Burden, Cancer Type, Metastasis Status, and Choice of Cancer Therapy Predict Overall … G Mestrallet Onco 5 (1), 8, 2025 | | 2025 |
| Coordinated macrophage and T cell interactions mediate response to checkpoint blockade in colorectal cancer. G Mestrallet, M Brown, N Vaninov, NW Cho, L Velazquez, ... bioRxiv, 2025.02. 12.637954, 2025 | | 2025 |
| Dendritic cells type 1 control the formation, maintenance, and function of tertiary lymphoid structures in cancer R Mattiuz, J Boumelha, P Hamon, J Le Berichel, A Vaidya, BY Soong, ... bioRxiv, 2024 | | 2024 |
| 551 Overcoming immune resistance in MMRd tumors G Mestrallet Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Immune response and resistance of clear cell renal cell carcinoma patients following immune checkpoint blockade G Mestrallet bioRxiv, 2023.10. 05.561140, 2023 | | 2023 |
| Predicting response and resistance to immune checkpoint blockade and surgery in melanoma patients G Mestrallet medRxiv, 2023.10. 05.23296626, 2023 | | 2023 |
| Enhancing immunotherapy outcomes in glioblastoma through predictive machine learning G Mestrallet medRxiv, 2023.10. 05.23296617, 2023 | | 2023 |